{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:33:35Z","timestamp":1788910415115,"version":"build-2803163510"},"reference-count":103,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0008649","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:22:50Z","timestamp":1601040170000},"page":"e0008649","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":54,"title":["Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0012-3436","authenticated-orcid":true,"given":"Grace","family":"Zdesenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Mutapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"issue":"16","key":"pntd.0008649.ref001","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1056\/NEJMra012396","article-title":"Schistosomiasis","volume":"346","author":"AGP Ross","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"pntd.0008649.ref002","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4269\/ajtmh.2003.69.318","article-title":"Geographic distribution of schistosomiasis and soil-transmitted helminths in Western Kenya: implications for anthelminthic mass treatment","volume":"69","author":"T Handzel","year":"2003","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"pntd.0008649.ref003","first-page":"17","article-title":"Integrated preventive chemotherapy for neglected tropical diseases: estimation of the number of interventions required and delivered, 2009\u20132010","volume":"87","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"issue":"13","key":"pntd.0008649.ref004","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1017\/S0031182009991600","article-title":"Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution","volume":"136","author":"J Utzinger","year":"2009","journal-title":"Parasitology"},{"key":"pntd.0008649.ref005","unstructured":"WHO. Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected diseases. 2013, World Health Organization. http:\/\/www.who.int\/iris\/handle\/10665\/77950."},{"issue":"1","key":"pntd.0008649.ref006","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1371\/journal.pntd.0000357","article-title":"Taste, A New Incentive to Switch to (R)-Praziquantel in Schistosomiasis Treatment","volume":"3","author":"T Meyer","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"issue":"Supp 1","key":"pntd.0008649.ref007","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s00436-002-0751-z","article-title":"Praziquantel","volume":"90","author":"D Cioli","year":"2003","journal-title":"Parasitol Res"},{"issue":"6","key":"pntd.0008649.ref008","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4155\/fmc.15.16","article-title":"Praziquantel: do we need another antischistosoma treatment?","volume":"7","author":"A Fenwick","year":"2015","journal-title":"Future Med Chem"},{"key":"pntd.0008649.ref009","article-title":"The mechanism of action of praziquantel: can new drugs exploit similar mechanisms?","author":"CM Thomas","year":"2018","journal-title":"Curr Med Chem"},{"issue":"6","key":"pntd.0008649.ref010","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/QCO.0b013e328318978f","article-title":"Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis","volume":"21","author":"MJ Doenhoff","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"pntd.0008649.ref011","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00389899","article-title":"Praziquantel, a new broad-spectrum antischistosomal agent","volume":"52","author":"R G\u00f6nnert","year":"1977","journal-title":"Z F Parasitenkunde"},{"issue":"10","key":"pntd.0008649.ref012","doi-asserted-by":"crossref","first-page":"e0006852","DOI":"10.1371\/journal.pntd.0006852","article-title":"Safety, efficacy and acceptability of praziquantel in the treatment of Schistosoma haematobium in pre-school children of Kwale County, Kenya","volume":"12","author":"BW Kimani","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"pntd.0008649.ref013","doi-asserted-by":"crossref","first-page":"e3286","DOI":"10.1371\/journal.pntd.0003286","article-title":"Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials","volume":"8","author":"J Zwang","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pntd.0008649.ref014","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.trstmh.2008.03.010","article-title":"Efficacy and side effects of praziquantel treatment against Schistosoma haematobium infection among primary school children in Zimbabwe","volume":"102","author":"N Midzi","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4","key":"pntd.0008649.ref015","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1017\/S003118201000154X","article-title":"Efficacy of two praziquantel treatments among primary school children in an area of high Schistosoma mansoni endemicity, Nile Delta","volume":"138","author":"R Barakat","year":"2010","journal-title":"Egypt. Parasitology"},{"issue":"6","key":"pntd.0008649.ref016","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4269\/ajtmh.2004.71.778","article-title":"Efficacy of Praziquantel against Schistosoma haematobium infection in children","volume":"71","author":"L-AT Tchuent\u00e9","year":"2004","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"pntd.0008649.ref017","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4269\/ajtmh.2006.74.342","article-title":"Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection","volume":"74","author":"D Alonso","year":"2006","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"pntd.0008649.ref018","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1471-4922(01)02209-7","article-title":"Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal","volume":"18","author":"A Danso-Appiah","year":"2002","journal-title":"Trends Parasitol"},{"issue":"1","key":"pntd.0008649.ref019","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40249-017-0293-3","article-title":"Efficacy of praziquantel on Schistosoma haematobium and re-infection rates among school-going children in the Ndumo area of uMkhanyakude district, KwaZulu-Natal, South Africa","volume":"6","author":"M Kabuyaya","year":"2017","journal-title":"Infect Dis Poverty"},{"issue":"3","key":"pntd.0008649.ref020","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0014-4894(86)90184-0","article-title":"Schistosoma mansoni: chemotherapy of infections of different ages","volume":"61","author":"AA Sabah","year":"1986","journal-title":"Exp Parasitol"},{"issue":"5","key":"pntd.0008649.ref021","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1128\/AAC.47.5.1487-1495.2003","article-title":"Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials","volume":"47","author":"J Utzinger","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0008649.ref022","unstructured":"WHO. Report of the Scientific Working Group Meeting on Schistosomiasis 2005, World Health Organization. https:\/\/apps.who.int\/iris\/handle\/10665\/69482."},{"issue":"9","key":"pntd.0008649.ref023","first-page":"759","article-title":"Susceptibility of Schistosoma japonicum to different developmental stages to praziquantel","volume":"100","author":"SH Xiao","year":"1987","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"pntd.0008649.ref024","doi-asserted-by":"crossref","first-page":"e02582","DOI":"10.1128\/AAC.02582-16","article-title":"Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance","volume":"61","author":"N Vale","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"pntd.0008649.ref025","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4155\/fmc.15.11","article-title":"What is the mechanism of action of praziquantel and how might resistance strike?","volume":"7","author":"PM Cupit","year":"2015","journal-title":"Future Med Chem"},{"key":"pntd.0008649.ref026","volume-title":"Cyprotex. Everything you need to know about ADME","year":"2015","edition":"2"},{"issue":"Database issue","key":"pntd.0008649.ref027","doi-asserted-by":"crossref","first-page":"D1113","DOI":"10.1093\/nar\/gkt1246","article-title":"The Transformer database: biotransformation of xenobiotics","volume":"42","author":"MF Hoffmann","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"pntd.0008649.ref028","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bcp.2014.05.001","article-title":"Metabolic profiling of praziquantel enantiomers","volume":"90","author":"HN Wang","year":"2014","journal-title":"Biochem Pharmacol"},{"issue":"5439","key":"pntd.0008649.ref029","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1126\/science.286.5439.487","article-title":"Pharmacogenomics: Translating functional genomics into rational therapeutics","volume":"286","author":"WE Evans","year":"1999","journal-title":"Science"},{"issue":"4","key":"pntd.0008649.ref030","first-page":"383","article-title":"Genetic polymorphism of cytochrome P450 and methods for its determination","volume":"107","author":"H Buzkova","year":"2006","journal-title":"Prague Med Rep"},{"issue":"5","key":"pntd.0008649.ref031","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0361-9230(97)00307-9","article-title":"Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants","volume":"44","author":"CM Masimirembwa","year":"1997","journal-title":"Brain Res Bull"},{"issue":"2","key":"pntd.0008649.ref032","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/clinchem\/43.2.254","article-title":"Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency","volume":"43","author":"MW Linder","year":"1997","journal-title":"Clin Chem"},{"issue":"2","key":"pntd.0008649.ref033","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.critrevonc.2005.03.007","article-title":"Drug\u2013drug interactions in oncology: Why are they important and can they be minimized?","volume":"55","author":"P Blower","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"pntd.0008649.ref034","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/jac\/dkt491","article-title":"The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer)","volume":"69","author":"P Olliaro","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"33\u201334","key":"pntd.0008649.ref035","first-page":"546","article-title":"Drug interactions-principles, examples and clinical consequences","volume":"109","author":"I Cascorbi","year":"2012","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"pntd.0008649.ref036","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/875512250602200105","article-title":"Cytochrome P450 Enzymes and Drug\u2014Drug Interactions: An Update on the Superfamily","volume":"22","author":"KAB Jeffrey D Lewis","year":"2006","journal-title":"J Pharm Technol"},{"issue":"6","key":"pntd.0008649.ref037","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/01.qco.0000247591.13671.6a","article-title":"Schistosomiasis: challenges for control, treatment and drug resistance","volume":"19","author":"A Fenwick","year":"2006","journal-title":"Curr Opin Infect Dis"},{"issue":"7","key":"pntd.0008649.ref038","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration","volume":"6","author":"A Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"pntd.0008649.ref039","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fphar.2014.00174","article-title":"Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research","volume":"5","author":"T Tuntland","year":"2014","journal-title":"Front Pharmacol"},{"issue":"1","key":"pntd.0008649.ref040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2013.10.040","article-title":"Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine","volume":"133","author":"VE Ortega","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"pntd.0008649.ref041","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/ajmg.a.31575","article-title":"Race and ethnicity in genetic research","volume":"143A","author":"P Sankar","year":"2007","journal-title":"Am J Med Genet A"},{"issue":"2","key":"pntd.0008649.ref042","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.exppara.2010.10.019","article-title":"Comparative efficacy and bioavailability of different praziquantel brands","volume":"127","author":"S Botros","year":"2011","journal-title":"Exp Parasitol"},{"issue":"6","key":"pntd.0008649.ref043","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1645\/GE-865R.1","article-title":"Drug-metabolizing enzymes and praziquantel bioavailability in mice harboring Schistosoma mansoni isolates of different drug susceptibilities","volume":"92","author":"S Botros","year":"2006","journal-title":"J Parasitol Res"},{"issue":"3","key":"pntd.0008649.ref044","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF03190204","article-title":"Effect of experimentally-induced hepatic cirrhosis on the pharmacokinetics of orally administered praziquantel in the rat","volume":"15","author":"GO Kokwaro","year":"1990","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"pntd.0008649.ref045","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1590\/S0074-02762011000200016","article-title":"Modulation of expression and activity of cytochrome P450s and alteration of praziquantel kinetics during murine schistosomiasis","volume":"106","author":"MA Gotardo","year":"2011","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"pntd.0008649.ref046","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jchromb.2017.02.013","article-title":"A quantification method for determination of racemate praziquantel and R-enantiomer in rat plasma for comparison of their pharmacokinetics","volume":"1048","author":"DL Zhang","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"pntd.0008649.ref047","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejpb.2019.06.029","article-title":"Activity and pharmacokinetics of a praziquantel crystalline polymorph in the Schistosoma mansoni mouse model","volume":"142","author":"FC Lombardo","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"pntd.0008649.ref048","unstructured":"WHO. Monitoring Anthelmintic Efficacy for Soil Transmitted Helminths (STH) 2008, World Health Organization. https:\/\/www.who.int\/neglected_diseases\/preventive_chemotherapy\/Chemotherapy_anthelminthic_drug_WHO_WB_final.pdf."},{"issue":"9","key":"pntd.0008649.ref049","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1128\/AAC.02741-14","article-title":"Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni","volume":"58","author":"I Meister","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pntd.0008649.ref050","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4269\/ajtmh.1989.41.198","article-title":"A comparison of the antischistosomal effect of levo- and dextro-praziquantel on Schistosoma japonicum and S. mansoni in mice","volume":"41","author":"M Tanaka","year":"1989","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pntd.0008649.ref051","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/cts.12601","article-title":"Relative bioavailability of orally dispersible tablet formulations of levo- and racemic praziquantel: two phase I studies","volume":"12","author":"WM Bagchus","year":"2019","journal-title":"Clin Transl Sci"},{"issue":"5","key":"pntd.0008649.ref052","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10928-018-9601-1","article-title":"Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale","volume":"45","author":"PL Bonate","year":"2018","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"27","key":"pntd.0008649.ref053","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1016\/j.jchromb.2009.07.036","article-title":"Enantioselective analysis of praziquantel and trans-4-hydroxypraziquantel in human plasma by chiral LC-MS\/MS: Application to pharmacokinetics","volume":"877","author":"RM Lima","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"4","key":"pntd.0008649.ref054","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2125.2010.03874.x","article-title":"Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity","volume":"71","author":"RM Lima","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"pntd.0008649.ref055","doi-asserted-by":"crossref","first-page":"809","DOI":"10.4269\/ajtmh.1994.51.809","article-title":"Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure","volume":"51","author":"MA el Guiniady","year":"1994","journal-title":"Am J Trop Med Hyg"},{"issue":"8","key":"pntd.0008649.ref056","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02253-17","article-title":"Pharmacokinetics of Praziquantel in Schistosoma mansoni- and Schistosoma haematobium-Infected School- and Preschool-Aged Children","volume":"62","author":"J Kovac","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pntd.0008649.ref057","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00007691-198810010-00008","article-title":"Oral praziquantel kinetics in normal and Schistosoma haematobium-infected subjects","volume":"10","author":"D Ofori-Adjei","year":"1988","journal-title":"Ther Drug Monit"},{"issue":"4","key":"pntd.0008649.ref058","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00227-16","article-title":"Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy","volume":"7","author":"AL Bustinduy","year":"2016","journal-title":"MBio"},{"issue":"6","key":"pntd.0008649.ref059","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1128\/AAC.41.6.1256","article-title":"Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen","volume":"41","author":"H Jung","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0008649.ref060","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jpba.2018.01.030","article-title":"Evaluation of a novel micro-sampling device, Mitra (TM), in comparison to dried blood spots, for analysis of praziquantel in Schistosoma haematobium-infected children in rural Cote d\u2019Ivoire","volume":"151","author":"J Kovac","year":"2018","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"pntd.0008649.ref061","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00560463","article-title":"Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics","volume":"14","author":"G Leopold","year":"1978","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"pntd.0008649.ref062","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/1043-6618(95)80048-4","article-title":"Impact of drug dosage and brand on bioavailability and efficacy of praziquantel","volume":"31","author":"A Metwally","year":"1995","journal-title":"Pharmacol Res"},{"issue":"3","key":"pntd.0008649.ref063","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0035-9203(90)90333-A","article-title":"Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis","volume":"84","author":"ME Mandour","year":"1990","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"10","key":"pntd.0008649.ref064","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1128\/AAC.44.10.2903-2904.2000","article-title":"Bioavailability of praziquantel increases with concomitant administration of food","volume":"44","author":"N Castro","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pntd.0008649.ref065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"GR Zimmermann","year":"2007","journal-title":"Drug Discov Today"},{"issue":"6","key":"pntd.0008649.ref066","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.apsb.2019.10.001","article-title":"Current trends in drug metabolism and pharmacokinetics","volume":"9","author":"Y Li","year":"2019","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"pntd.0008649.ref067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"JS Kang","year":"2009","journal-title":"Korean J Intern Med"},{"issue":"1","key":"pntd.0008649.ref068","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/msb.2011.71","article-title":"Systematic exploration of synergistic drug pairs","volume":"7","author":"M Cokol","year":"2011","journal-title":"Mol Syst Biol"},{"issue":"3","key":"pntd.0008649.ref069","doi-asserted-by":"crossref","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"J Foucquier","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"pntd.0008649.ref070","volume-title":"Drug therapy in nursing","author":"DS Aschenbrenner","year":"2009"},{"issue":"6","key":"pntd.0008649.ref071","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1039\/C9NP00011A","article-title":"Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2","volume":"36","author":"LK Caesar","year":"2019","journal-title":"Nat Prod Rep"},{"issue":"158","key":"pntd.0008649.ref072","article-title":"An Introduction to Terminology and Methodology of Chemical Synergy\u2014Perspectives from Across Disciplines","volume":"8","author":"KR Roell","year":"2017","journal-title":"Front Pharmacol"},{"issue":"7","key":"pntd.0008649.ref073","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1590\/S0074-02762011000700006","article-title":"Pharmacodynamics of mefloquine and praziquantel combination therapy in mice harbouring juvenile and adult Schistosoma mansoni","volume":"106","author":"NM El-Lakkany","year":"2011","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"1","key":"pntd.0008649.ref074","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0001-706X(01)00138-3","article-title":"Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals","volume":"80","author":"J Utzinger","year":"2001","journal-title":"Acta Tropica"},{"issue":"9","key":"pntd.0008649.ref075","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1600-0463.2010.02645.x","article-title":"Praziquantel efficacy in mice infected with PZQ non-susceptible S. mansoni isolate treated with artemether: Parasitological, biochemical and immunohistochemical assessment","volume":"118","author":"S Botros","year":"2010","journal-title":"APMIS"},{"issue":"9","key":"pntd.0008649.ref076","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/jac\/dkq233","article-title":"Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice","volume":"65","author":"J Keiser","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"pntd.0008649.ref077","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-0463.2007.apm_501.x","article-title":"Pharmacodynamics of pentoxifylline and\/or praziquantel in murine schistosomiasis mansoni","volume":"115","author":"N El-Lakkany","year":"2007","journal-title":"APMIS"},{"issue":"7\u20138","key":"pntd.0008649.ref078","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1600-0463.2006.apm_380.x","article-title":"Effect of adamantylamide dipeptide as adjuvant therapy to praziquantel in mice infected with different S. mansoni isolates","volume":"114","author":"S Botros","year":"2006","journal-title":"APMIS"},{"issue":"Supplement 1","key":"pntd.0008649.ref079","first-page":"136","article-title":"Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the schistosoma mansoni mouse model: Possible clinical implications","volume":"22","author":"N Abla","year":"2017","journal-title":"Trop Med Int Health"},{"issue":"4","key":"pntd.0008649.ref080","first-page":"587","article-title":"Evaluation of the Anti-schistosomal Effects of Turmeric (Curcuma longa) Versus Praziquantel in Schistosoma mansoni Infected Mice","volume":"12","author":"A Hussein","year":"2017","journal-title":"Iran J Parasitol"},{"issue":"3","key":"pntd.0008649.ref081","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF03188806","article-title":"Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics of praziquantel in rats","volume":"18","author":"CM Masimirembwa","year":"1993","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"8","key":"pntd.0008649.ref082","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1590\/S0074-02762008000800007","article-title":"Association of oxamniquine, praziquantel, and clonazepam in experimental Schistosomiasis mansoni","volume":"103","author":"N Araujo","year":"2008","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"4","key":"pntd.0008649.ref083","first-page":"519","article-title":"Efficacy of a combination of Metrifonate and praziquantel in the treatment of Schistosoma-mansoni infection in albino mice","volume":"45-1","author":"FA Ebeid","year":"1995","journal-title":"Arzneimittelforschung"},{"issue":"8","key":"pntd.0008649.ref084","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00228-019-02663-8","article-title":"The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel","volume":"75","author":"L Nleya","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"pntd.0008649.ref085","first-page":"516","article-title":"Effect of cimetidine, bicarbonate and glucose on the bioavailability of different formulations of praziquantel","volume":"45-1","author":"A Metwally","year":"1995","journal-title":"Arzneimittelforschung"},{"issue":"1","key":"pntd.0008649.ref086","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/bdd.2510150103","article-title":"The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and in humans","volume":"15","author":"CM Masimirembwa","year":"1994","journal-title":"Biopharm Drug Dispos"},{"issue":"7456","key":"pntd.0008649.ref087","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/bmj.329.7456.27","article-title":"Interaction of St John\u2019s wort with conventional drugs: systematic review of clinical trials","volume":"329","author":"E Mills","year":"2004","journal-title":"BMJ"},{"issue":"5","key":"pntd.0008649.ref088","first-page":"381","article-title":"Biotransformation of praziquantel by human cytochrome p450 3A4 (CYP 3A4)","volume":"63","author":"A Godawska-Matysik","year":"2006","journal-title":"Acta Pol Pharm"},{"issue":"5\u20136","key":"pntd.0008649.ref089","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0731-7085(01)00470-8","article-title":"Isolation and identification of 8-hydroxypraziquantel as a metabolite of the antischistosomal drug praziquantel","volume":"26","author":"D Schepmann","year":"2001","journal-title":"J Pharm Biomed Anal"},{"key":"pntd.0008649.ref090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/B978-0-12-800780-8.00004-8","volume-title":"Organic Chemistry","author":"RJ Ouellette","year":"2014"},{"key":"pntd.0008649.ref091","unstructured":"Consortium PP. The pediatric formulation. Pediatric Praziquantel Consortium. 2020. https:\/\/www.pediatricpraziquantelconsortium.org\/pediatric-formulation."},{"issue":"7","key":"pntd.0008649.ref092","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2214-109X(17)30187-0","article-title":"Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial","volume":"5","author":"JT Coulibaly","year":"2017","journal-title":"Lancet Glob Health"},{"key":"pntd.0008649.ref093","doi-asserted-by":"crossref","unstructured":"Khojasteh S.C. WH, Hop C.E.C.A. Drug Metabolism and Pharmacokinetics Quick Guide: Oral Absorption. New York, NY: Springer; 2011.","DOI":"10.1007\/978-1-4419-5629-3"},{"issue":"4","key":"pntd.0008649.ref094","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects","volume":"102","author":"Y Zhou","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"pntd.0008649.ref095","unstructured":"WHO. Schistosomiasis: World Health Organization; 2018. http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/schistosomiasis."},{"issue":"1","key":"pntd.0008649.ref096","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40249-017-0300-8","article-title":"Putting the treatment of paediatric schistosomiasis into context","volume":"6","author":"T Mduluza","year":"2017","journal-title":"Infect Dis Poverty"},{"key":"pntd.0008649.ref097","first-page":"27","volume-title":"Molecular Mechanisms to Clinical Applications. Chemistry for Sustainable Development in Africa","author":"C Masimirembwa","year":"2013"},{"issue":"8","key":"pntd.0008649.ref098","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/jac\/dkr178","article-title":"Interactions of mefloquine with praziquantel in the schistosoma mansoni mouse model and in vitro","volume":"66","author":"J Keiser","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"pntd.0008649.ref099","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jgar.2015.08.004","article-title":"Monitoring the efficacy of drugs for neglected tropical diseases controlled by preventive chemotherapy","volume":"3","author":"M Albonico","year":"2015","journal-title":"J Glob Antimicrob Resist"},{"issue":"5","key":"pntd.0008649.ref100","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/00034983.1994.11812903","article-title":"Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men","volume":"88","author":"M Homeida","year":"1994","journal-title":"Ann Trop Med Parasitol"},{"key":"pntd.0008649.ref101","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1179\/000349804225003398","article-title":"Pharmacokinetic investigation of albendazole and praziquantel in Thai children infected with Giardia intestinalis","volume":"98","author":"K Pengsaa","year":"2004","journal-title":"Ann Trop Med Parasitol"},{"key":"pntd.0008649.ref102","first-page":"277","article-title":"Drug\u2013Drug interactions","volume":"71","author":"AD Rodrigues","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"key":"pntd.0008649.ref103","first-page":"1","volume-title":"Drug Discovery and Evaluation: Methods in Clinical Pharmacology","author":"K Abo-EL-Sooud","year":"2018"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0008649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T02:20:57Z","timestamp":1617502857000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0008649"}},"subtitle":[],"editor":[{"given":"John Stuart","family":"Gilleard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":103,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0008649","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]}}}